论文部分内容阅读
目的:探索不同时机应用EGFR-TKI(一线治疗VS二/三线治疗)对晚期肺腺癌患者总生存的影响。方法:回顾性分析IV期肺腺癌患者的临床资料。比较一线治疗组与二/三线治疗组的临床基线特征、近期疗效等方面的差异。结果:EGFR-TKI二/三线治疗组的总生存时间显著优于一线治疗组,在其它方面无显著差异。结论:EGFR-TKI二/三线治疗可能要优于一线治疗。
Objective: To explore the different timing of the application of EGFR-TKI (first-line treatment of VS second / third line treatment) on the overall survival of patients with advanced lung cancer. Methods: The clinical data of patients with stage IV lung adenocarcinoma were retrospectively analyzed. Compare the baseline characteristics of the first-line treatment group with the second / third line treatment group, the recent efficacy and other aspects. RESULTS: The overall survival of the EGFR-TKI second- and third-line treatment group was significantly better than the first-line treatment group, with no significant difference in other areas. Conclusions: Second and third-line EGFR-TKI therapy may be superior to first-line therapy.